T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BKV
2601
BKV Corp
BKV
$2.84B
| $324K | ﹤0.01% |
11,897
+3,050
| +34% | +$76.6K |
|
|
OPTU
2602
Optimum Communications Inc
OPTU
$228M
| $323K | ﹤0.01% |
195,452
| – | – |
|
2603
SmartFinancial
SMBK
$899M
| $321K | ﹤0.01% |
8,674
+1,007
| +13% | +$36.5K |
|
2604
Cooper-Standard Automotive
CPS
$484M
| $320K | ﹤0.01% |
9,734
+818
| +9% | +$26.6K |
|
|
SRG
2605
Seritage Growth Properties
SRG
$128M
| $320K | ﹤0.01% |
98,256
| – | – |
|
2606
United States Antimony
UAMY
$799M
| $317K | ﹤0.01% |
63,085
+14,351
| +29% | +$113K |
|
2607
Methode Electronics
MEI
$593M
| $316K | ﹤0.01% |
47,522
| – | – |
|
2608
Consolidated Water Co
CWCO
$502M
| $315K | ﹤0.01% |
8,924
+905
| +11% | +$31.6K |
|
2609
ImmunityBio
IBRX
$8.11B
| $314K | ﹤0.01% |
158,242
+37,188
| +31% | +$84.3K |
|
|
PKST
2610
DELISTED
Peakstone Realty Trust
PKST
| $314K | ﹤0.01% |
21,879
+2,330
| +12% | +$32.1K |
|
|
GDEN
2611
DELISTED
Golden Entertainment
GDEN
| $313K | ﹤0.01% |
11,507
+1,158
| +11% | +$30K |
|
|
SLDE
2612
Slide Insurance Holdings
SLDE
$2.52B
| $313K | ﹤0.01% |
16,019
+1,704
| +12% | +$28.4K |
|
2613
Vanda Pharmaceuticals
VNDA
$304M
| $312K | ﹤0.01% |
35,283
+6,027
| +21% | +$33.2K |
|
2614
Clearfield
CLFD
$390M
| $310K | ﹤0.01% |
10,618
+635
| +6% | +$20.4K |
|
2615
Idaho Strategic Resources
IDR
$500M
| $310K | ﹤0.01% |
7,673
+977
| +15% | +$37.3K |
|
2616
MetroCity Bankshares
MCBS
$1.05B
| $309K | ﹤0.01% |
11,640
+1,373
| +13% | +$36.6K |
|
2617
ACNB Corp
ACNB
$660M
| $307K | ﹤0.01% |
6,333
+913
| +17% | +$43.1K |
|
2618
Alerus Financial
ALRS
$844M
| $307K | ﹤0.01% |
13,594
+1,318
| +11% | +$28.7K |
|
|
VTYX
2619
DELISTED
Ventyx Biosciences
VTYX
| $307K | ﹤0.01% |
33,977
-35,100
| -51% | -$262K |
|
2620
Dream Finders Homes
DFH
$1.35B
| $306K | ﹤0.01% |
17,885
+1,407
| +9% | +$28.8K |
|
2621
Pacific Biosciences
PACB
$357M
| $306K | ﹤0.01% |
163,527
+17,663
| +12% | +$33.9K |
|
2622
RCI Hospitality Holdings
RICK
$230M
| $306K | ﹤0.01% |
12,799
+2,200
| +21% | +$56.3K |
|
2623
Talkspace
TALK
$871M
| $306K | ﹤0.01% |
84,241
+1,448
| +2% | +$4.59K |
|
2624
Distribution Solutions Group
DSGR
$1.61B
| $305K | ﹤0.01% |
11,114
+3,385
| +44% | +$95.2K |
|
|
NB
2625
NioCorp Developments
NB
$745M
| $304K | ﹤0.01% |
57,242
+19,997
| +54% | +$138K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.